<p>Ardelyx, Inc.（纳斯达克股票代码：ARDX - 获取免费报告）的股价在周五交易中跌破了其 200 日移动平均线。该股的 200 日移动平均价为 7.21 美元，最低交易价为 5.76 美元。Ardelyx 股票最近以 5.85 美元交易，成交量为 2,695,116 股。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>华尔街看好的 3 只低于 20 美元的中盘股</li>
</ul>
<p>多位研究分析师发布了关于该股的报告。Piper Sandler 将 Ardelyx 股票的评级从 “增持” 调降至 “中性”，并在 7 月 2 日星期二的研究报告中将其目标股价从 15.00 美元降至 7.00 美元。StockNews.com 在 7 月 31 日的报告中将 Ardelyx 股票的评级从 “卖出” 调升至 “持有”。花旗集团将 Ardelyx 的目标股价从 10.00 美元调高至 12.00 美元，并在 8 月 2 日星期五的研究报告中给予该公司 “买入” 评级。HC Wainwright 将 Ardelyx 的目标股价从 10.00 美元调高至 11.00 美元，并在 8 月 5 日星期一的研究报告中给予该股 “买入” 评级。最后，Cantor Fitzgerald 在 6 月 20 日星期四的研究报告中重申了对 Ardelyx 股票的 “增持” 评级。两位研究分析师对该股进行了持有评级，六位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat 的数据，该股的平均评级为 “中等买入”，共识目标股价为 11.43 美元。</p>
<p><strong>阅读我们关于 ARDX 的最新股票报告</strong></p>
<h2>Ardelyx 股票表现</h2>
<ul>
<li>2022 年初下滑后，Ardelyx 是否值得买入</li>
</ul>
<p>该公司的五十日移动平均股价为 5.91 美元，两百日移动平均股价为 7.21 美元。该公司的市值为 13.6 亿美元，市盈率为-20.89，贝塔系数为 0.83。公司的资产负债比为 0.66，流动比率为 4.53，速动比率为 4.36。</p>
<p>Ardelyx（纳斯达克股票代码：ARDX - 获取免费报告）于 8 月 1 日星期四公布了其季度财报。这家生物制药公司在该季度报告中每股亏损 0.07 美元，超过了每股亏损 0.11 美元的共识预期 0.04 美元。Ardelyx 的净利润率为-31.02%，净资产收益率为-38.41%。该公司在该季度实现了 7,320 万美元的营收，超过了分析师对 5503 万美元的预期。去年同期，该公司每股亏损为 0.08 美元。作为一组，股票研究分析师预计 Ardelyx, Inc.今年将实现每股-0.34 美元的盈利。</p>
<h2>内部人士押注</h2>
<p>另外，首席执行官 Michael Raab 于 7 月 29 日星期一以 5.64 美元的平均价格出售了 30,000 股股票。该交易总价值为 169,200.00 美元。交易完成后，首席执行官在公司拥有 1,260,463 股股票，价值约 7,109,011.32 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过此超链接查看。此外，内部人士 David P. Rosenbaum 于 6 月 3 日星期一以 7.00 美元的平均价格出售了 17,872 股 Ardelyx 股票。这些股票的总价值为 125,104.00 美元。交易完成后，该内部人士现在直接持有公司股票 158,502 股，价值 1,109,514 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过此超链接访问。此外，首席执行官 Michael Raab 于 7 月 29 日星期一以 5.64 美元的平均价格出售了 30,000 股公司股票。这些股票的总价值为 169,200.00 美元。交易完成后，首席执行官现在持有公司股票 1,260,463 股，价值约 7,109,011.32 美元。此次交易的披露信息可在此处找到。过去 90 天内，内部人士已出售了价值 1,903,349 美元的 284,411 股公司股票。公司股份的 5.50% 归内部人士所有。</p>
<h2>Ardelyx 的机构交易</h2>
<p>大型投资者最近增加或减少了对该公司的持股。Eventide Asset Management LLC 在第四季度增持了 Ardelyx 股票，持股增长了 152.5%，现在拥有 680 万 5494 股这家生物制药公司的股票，价值 4219.4 万美元，比上一季度增加了 411 万 494 股。Redmile Group LLC 在第一季度收购了 Ardelyx 的新股，价值约 1602 万美元。Millennium Management LLC 在第二季度增持了 Ardelyx 的股份，持股增长了 142.8%，现在拥有 320 万 3090 股这家生物制药公司的股票，价值 2373.5 万美元，比上一季度增加了 188 万 3995 股。Price T Rowe Associates Inc. MD 在第一季度增持了 Ardelyx 的股份，持股增长了 68.0%，现在拥有 391 万 3863 股这家生物制药公司的股票，价值 2857.2 万美元，比上一季度增加了 158 万 4597 股。最后，Rubric Capital Management LP 在第四季度增持了 Ardelyx 的股份，持股增长了 60.5%，现在拥有 401 万 2753 股这家生物制药公司的股票，价值 2487.9 万美元，比上一季度增加了 151 万 2753 股。58.92% 的股份由机构投资者和对冲基金持有。</p>
<h2>关于 Ardelyx（获取免费报告）</h2>
<p>Ardelyx, Inc.是一家生物制药公司，致力于在美国和国际市场上发现、开发和销售治疗胃肠和心脏肾脏疾病的药物。该公司的主要产品候选药物是 tenapanor，用于治疗具有便秘型肠易激综合征的患者。</p>
<h2>更多阅读</h2>
<ul>
<li>五只我们比 Ardelyx 更喜欢的股票</li>
<li>科技股解析：关于科技的要点</li>
<li>京东盈利惊喜：中国前景好于预期</li>
<li>投资高市盈率成长股</li>
<li>沃伦·巴菲特最近的股票操作：值得关注的热门买卖</li>
<li>什么是分红收割策略，投资者如何从中获利？</li>
<li>Sea Limited 的电商和金融科技实力推动股价飙升</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 2024 年科技恐慌：亿万富翁知道的你不知道的（来自 InvestorPlace）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5"/></p>
<h2>现在是否值得投资$1,000 在 Ardelyx？</h2>
<p>在考虑 Ardelyx 之前，您需要听到这个消息。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Ardelyx 不在其中。</p>
<p>虽然 Ardelyx 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ARDX

<p>Ardelyx（纳斯达克股票代码：ARDX）股价跌破了其 200 日移动平均线的 0.21 美元，最低交易价为 0.76 美元。分析师对该股褒贬不一，Piper Sandler 将股票评级下调至 “中性”，并降低目标价。相反，花旗集团和 HC Wainwright 则上调了评级。财务数据显示季度营收增长了 228.3%，但每股收益仍为负值，为-0.07 美元。近期有大量内部人士减持股份，机构投资者也在积极交易。该股的平均评级为 “中等买入”，共识目标价为 0.43 美元</p>

<p>Shares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $7.21 and traded as low as $5.76. Ardelyx shares last traded at $5.85, with a volume of 2,695,116 shares.</p>
<div class="lb-trans"><p>Ardelyx, Inc.（纳斯达克股票代码：ARDX - 获取免费报告）的股价在周五交易中跌破了其 200 日移动平均线。该股的 200 日移动平均价为 7.21 美元，最低交易价为 5.76 美元。Ardelyx 股票最近以 5.85 美元交易，成交量为 2,695,116 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<ul>
<li>3 mid-caps under $20 that Wall Street loves</li>
</ul>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
<ul>
<li>华尔街看好的 3 只低于 20 美元的中盘股</li>
</ul>
</div><p>A number of research analysts have issued reports on the stock. Piper Sandler cut shares of Ardelyx from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and decreased their target price for the stock from $15.00 to $7.00 in a research report on Tuesday, July 2nd. StockNews.com raised Ardelyx from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, July 31st. Citigroup lifted their target price on Ardelyx from $10.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 2nd. HC Wainwright increased their price target on Ardelyx from $10.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, August 5th. Finally, Cantor Fitzgerald restated an &#34;overweight&#34; rating on shares of Ardelyx in a research note on Thursday, June 20th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $11.43.</p>
<div class="lb-trans"><p>多位研究分析师发布了关于该股的报告。Piper Sandler 将 Ardelyx 股票的评级从 “增持” 调降至 “中性”，并在 7 月 2 日星期二的研究报告中将其目标股价从 15.00 美元降至 7.00 美元。StockNews.com 在 7 月 31 日的报告中将 Ardelyx 股票的评级从 “卖出” 调升至 “持有”。花旗集团将 Ardelyx 的目标股价从 10.00 美元调高至 12.00 美元，并在 8 月 2 日星期五的研究报告中给予该公司 “买入” 评级。HC Wainwright 将 Ardelyx 的目标股价从 10.00 美元调高至 11.00 美元，并在 8 月 5 日星期一的研究报告中给予该股 “买入” 评级。最后，Cantor Fitzgerald 在 6 月 20 日星期四的研究报告中重申了对 Ardelyx 股票的 “增持” 评级。两位研究分析师对该股进行了持有评级，六位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat 的数据，该股的平均评级为 “中等买入”，共识目标股价为 11.43 美元。</p>
</div><p><strong>Read Our Latest Stock Report on ARDX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ARDX 的最新股票报告</strong></p>
</div><h2>Ardelyx Stock Performance</h2>
<ul>
<li>Is Ardelyx is A Buy After Slip in Early 2022</li>
</ul>
<div class="lb-trans"><h2>Ardelyx 股票表现</h2>
<ul>
<li>2022 年初下滑后，Ardelyx 是否值得买入</li>
</ul>
</div><p>The company has a fifty day moving average price of $5.91 and a two-hundred day moving average price of $7.21. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -20.89 and a beta of 0.83. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.53 and a quick ratio of 4.36.</p>
<div class="lb-trans"><p>该公司的五十日移动平均股价为 5.91 美元，两百日移动平均股价为 7.21 美元。该公司的市值为 13.6 亿美元，市盈率为-20.89，贝塔系数为 0.83。公司的资产负债比为 0.66，流动比率为 4.53，速动比率为 4.36。</p>
</div><p>Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. Ardelyx had a negative net margin of 31.02% and a negative return on equity of 38.41%. The company had revenue of $73.20 million during the quarter, compared to analyst estimates of $55.03 million. During the same quarter last year, the firm posted ($0.08) EPS. The business's revenue for the quarter was up 228.3% on a year-over-year basis. As a group, equities research analysts expect that Ardelyx, Inc. will post -0.34 EPS for the current year.</p>
<div class="lb-trans"><p>Ardelyx（纳斯达克股票代码：ARDX - 获取免费报告）于 8 月 1 日星期四公布了其季度财报。这家生物制药公司在该季度报告中每股亏损 0.07 美元，超过了每股亏损 0.11 美元的共识预期 0.04 美元。Ardelyx 的净利润率为-31.02%，净资产收益率为-38.41%。该公司在该季度实现了 7,320 万美元的营收，超过了分析师对 5503 万美元的预期。去年同期，该公司每股亏损为 0.08 美元。作为一组，股票研究分析师预计 Ardelyx, Inc.今年将实现每股-0.34 美元的盈利。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士押注</h2>
</div><p>In other news, CEO Michael Raab sold 30,000 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $5.64, for a total transaction of $169,200.00. Following the completion of the sale, the chief executive officer now owns 1,260,463 shares in the company, valued at approximately $7,109,011.32. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. In other news, insider David P. Rosenbaum sold 17,872 shares of Ardelyx stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $7.00, for a total value of $125,104.00. Following the transaction, the insider now directly owns 158,502 shares of the company's stock, valued at $1,109,514. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael Raab sold 30,000 shares of the company's stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $5.64, for a total transaction of $169,200.00. Following the completion of the sale, the chief executive officer now owns 1,260,463 shares of the company's stock, valued at approximately $7,109,011.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 284,411 shares of company stock worth $1,903,349. 5.50% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>另外，首席执行官 Michael Raab 于 7 月 29 日星期一以 5.64 美元的平均价格出售了 30,000 股股票。该交易总价值为 169,200.00 美元。交易完成后，首席执行官在公司拥有 1,260,463 股股票，价值约 7,109,011.32 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过此超链接查看。此外，内部人士 David P. Rosenbaum 于 6 月 3 日星期一以 7.00 美元的平均价格出售了 17,872 股 Ardelyx 股票。这些股票的总价值为 125,104.00 美元。交易完成后，该内部人士现在直接持有公司股票 158,502 股，价值 1,109,514 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过此超链接访问。此外，首席执行官 Michael Raab 于 7 月 29 日星期一以 5.64 美元的平均价格出售了 30,000 股公司股票。这些股票的总价值为 169,200.00 美元。交易完成后，首席执行官现在持有公司股票 1,260,463 股，价值约 7,109,011.32 美元。此次交易的披露信息可在此处找到。过去 90 天内，内部人士已出售了价值 1,903,349 美元的 284,411 股公司股票。公司股份的 5.50% 归内部人士所有。</p>
</div><h2>Institutional Trading of Ardelyx</h2>
<div class="lb-trans"><h2>Ardelyx 的机构交易</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Eventide Asset Management LLC grew its holdings in shares of Ardelyx by 152.5% during the fourth quarter. Eventide Asset Management LLC now owns 6,805,494 shares of the biopharmaceutical company's stock valued at $42,194,000 after buying an additional 4,110,494 shares in the last quarter. Redmile Group LLC acquired a new stake in Ardelyx during the 1st quarter worth about $16,020,000. Millennium Management LLC grew its stake in Ardelyx by 142.8% during the 2nd quarter. Millennium Management LLC now owns 3,203,090 shares of the biopharmaceutical company's stock valued at $23,735,000 after acquiring an additional 1,883,995 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Ardelyx by 68.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,913,863 shares of the biopharmaceutical company's stock valued at $28,572,000 after purchasing an additional 1,584,597 shares during the period. Finally, Rubric Capital Management LP lifted its position in shares of Ardelyx by 60.5% in the fourth quarter. Rubric Capital Management LP now owns 4,012,753 shares of the biopharmaceutical company's stock worth $24,879,000 after purchasing an additional 1,512,753 shares in the last quarter. 58.92% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该公司的持股。Eventide Asset Management LLC 在第四季度增持了 Ardelyx 股票，持股增长了 152.5%，现在拥有 680 万 5494 股这家生物制药公司的股票，价值 4219.4 万美元，比上一季度增加了 411 万 494 股。Redmile Group LLC 在第一季度收购了 Ardelyx 的新股，价值约 1602 万美元。Millennium Management LLC 在第二季度增持了 Ardelyx 的股份，持股增长了 142.8%，现在拥有 320 万 3090 股这家生物制药公司的股票，价值 2373.5 万美元，比上一季度增加了 188 万 3995 股。Price T Rowe Associates Inc. MD 在第一季度增持了 Ardelyx 的股份，持股增长了 68.0%，现在拥有 391 万 3863 股这家生物制药公司的股票，价值 2857.2 万美元，比上一季度增加了 158 万 4597 股。最后，Rubric Capital Management LP 在第四季度增持了 Ardelyx 的股份，持股增长了 60.5%，现在拥有 401 万 2753 股这家生物制药公司的股票，价值 2487.9 万美元，比上一季度增加了 151 万 2753 股。58.92% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>About Ardelyx (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Ardelyx（获取免费报告）</h2>
</div><p>Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.</p>
<div class="lb-trans"><p>Ardelyx, Inc.是一家生物制药公司，致力于在美国和国际市场上发现、开发和销售治疗胃肠和心脏肾脏疾病的药物。该公司的主要产品候选药物是 tenapanor，用于治疗具有便秘型肠易激综合征的患者。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Ardelyx</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>JD.com Earnings Surprise: China’s Outlook Better Than Expected</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch</li>
<li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li>
<li>Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge</li>
</ul>
<div class="lb-trans"><h2>更多阅读</h2>
<ul>
<li>五只我们比 Ardelyx 更喜欢的股票</li>
<li>科技股解析：关于科技的要点</li>
<li>京东盈利惊喜：中国前景好于预期</li>
<li>投资高市盈率成长股</li>
<li>沃伦·巴菲特最近的股票操作：值得关注的热门买卖</li>
<li>什么是分红收割策略，投资者如何从中获利？</li>
<li>Sea Limited 的电商和金融科技实力推动股价飙升</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ The 2024 Tech Panic: What Billionaires Know That You Don’t (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 2024 年科技恐慌：亿万富翁知道的你不知道的（来自 InvestorPlace）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9179&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Ardelyx right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Ardelyx？</h2>
</div><p>Before you consider Ardelyx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ardelyx 之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Ardelyx 不在其中。</p>
</div><p>While Ardelyx currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ardelyx 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Ardelyx（纳斯达克：ARDX）股价跌破 200 日移动平均线 7.21 美元